Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

1 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2009-011523-31-GB (EUCTR)	23/06/2009	16/04/2009	A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC	A study of the immune response to vaccination in MS patients treated with alemtuzumab - CAM-VAC	The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab. MedDRA version: 9.1;Level: PT;Classification code 10063399;Term: Relapsing-remitting multiple sclerosis MedDRA version: 9.1;Classification code 10063400;Term: Secondary progressive multiple sclerosis MedDRA version: 9.1;Level: LLT;Classification code 10046859;Term: Vaccination	Trade Name: Menitorix Trade Name: Pneumovax II Trade Name: REVAXIS	R & D, Cambridge University Hospitals	NULL	Not Recruiting			Female: yes Male: yes	60		United Kingdom